Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App





Nasopharyngeal Swabs More Effective Than Saliva Tests at Detecting COVID-19

By LabMedica International staff writers
Posted on 06 Jun 2022

A new study has found that nasopharyngeal swabs – taken from far back inside the nostril – were more effective at detecting COVID-19 than saliva tests or swabs just inside the nostril or under the tongue. More...

The study also found that detection rates were lower in asymptomatic patients, confirming the rationale for shortened isolation guidelines.

For the study, researchers at Cornell University (Ithaca, NY, USA) used different samples from patients: nasopharyngeal swabs, anterior nares swabs (front of the nostril), saliva and sublingual swabs (under the tongue). The researchers also collected samples from symptomatic, asymptomatic and post-symptomatic individuals – those who had recovered from illness – to better understand testing efficiency in these populations. When they compared the different sample types, the researchers found that nasopharyngeal samples provided the best rate of detection, from 92 to 100%. This is likely because the virus replicates in the nasal turbinate, the tissue structures in the uppermost portion of the nose.

Detection rates from anterior nares and saliva specimens were slightly lower, at 92 to 96% for symptomatic patients. This detection rate was lower when the samples that came from asymptomatic patients (75% to 92%). SARS-CoV-2 detection of sublingual specimens was much poorer, with detection rates of only 40 to 60% from symptomatic patient specimens and 25% to 42% from asymptomatic patient specimens. Detection rates in symptomatic, asymptomatic and post-symptomatic patients was fairly intuitive, with detection being most robust in symptomatic patients, ranging from 92 to 100%, depending on the test used. For all tests, the virus was slightly harder to detect in asymptomatic patients, at a rate of 75 to 96%. Once symptoms were resolved in post-symptomatic patients, detection was much more difficult.

The team also investigated infectivity – the level of infectious viral particles excreted in each of the sample types and from the different patient categories. As predicted, the most infectious samples came from symptomatic patients, while fewer than one-third of specimens collected from asymptomatic patients were infectious. The researchers were unable to isolate any infectious virus from post-symptomatic patient samples. This new data gives health practitioners some practical guidance.

“The study addressed the very important issue of identifying a sample type that would allow reliable detection of the virus, without significantly compromising the sensitivity of detection,” said Dr. Diego Diel, associate professor in the Department of Population Medicine and Diagnostic Sciences and director of the virology laboratory at the Animal Health Diagnostic Center, who was lead author of the study. “We were surprised at the relatively short period in which infectious virus was detected.”

Related Links:
Cornell University 


Platinum Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.